» Articles » PMID: 15286469

Folate Intake, MTHFR C677T Polymorphism, Alcohol Consumption, and Risk for Sporadic Colorectal Adenoma (United States)

Overview
Specialties Oncology
Public Health
Date 2004 Aug 3
PMID 15286469
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purpose of this study was to investigate whether folate intake is associated with risk for incident sporadic colorectal adenoma, and whether the association differs according to methylenetetrahydrofolate reductase (MTHFR) genotypes or is modified by intakes of alcohol or other micronutrients in the folate metabolism pathway.

Methods: The authors analyzed data from a colonoscopy-based case-control study (n = 177 cases, 228 controls) conducted in North Carolina between 1995 and 1997.

Results: The multivariate-adjusted odds ratio (OR) comparing the highest to lowest tertile of total folate intake was 0.61 (95% confidence interval [CI] 0.35-1.05); for MTHFR C677T polymorphism CT and TT genotypes relative to the CC genotype they were, respectively, 1.09 (CI: 0.71-1.66) and 0.68 (CI: 0.29-1.61); and for heavy drinkers (> 3 drinks/week) compared to non-drinkers it was 1.67 (CI: 1.00-2.81). The multivariate-adjusted ORs comparing the highest to lowest tertile of total folate intake according to those with the MTHFR CC, CT, and TT genotypes, were, respectively, 0.65 (CI: 0.30-1.39), 0.57 (CI: 0.23-1.44), and 0.22 (CI: 0.02-3.19). For those in the lowest tertile of folate intake who drank more than three drinks a week compared to those who were in the highest tertile of folate intake and did not drink alcohol the OR was 6.54 (CI: 1.96-21.80). There was no substantial evidence for interactions of folate with intakes of methionine, vitamins B2, B6, or B12.

Conclusions: These data are consistent with hypotheses and previous findings that higher folate intake may reduce risk for colorectal neoplasms, perhaps especially among those who consume more alcohol.

Citing Articles

Associations of DNA Base Excision Repair and Antioxidant Enzyme Genetic Risk Scores with Biomarker of Systemic Inflammation.

Mao Z, Gray A, Gross M, Thyagarajan B, Bostick R Front Aging. 2022; 3:897907.

PMID: 36338835 PMC: 9632613. DOI: 10.3389/fragi.2022.897907.


Simultaneous quantitation of folates, flavins and B metabolites in human plasma by LC-MS/MS assay: Applications in colorectal cancer.

Asante I, Pei H, Zhou E, Liu S, Chui D, Yoo E J Pharm Biomed Anal. 2018; 158:66-73.

PMID: 29860180 PMC: 7473779. DOI: 10.1016/j.jpba.2018.05.030.


Circulating folate levels and colorectal adenoma: a case-control study and a meta-analysis.

Park Y, Youn J, Cho C, Kim S, Lee J Nutr Res Pract. 2017; 11(5):419-429.

PMID: 28989579 PMC: 5621365. DOI: 10.4162/nrp.2017.11.5.419.


Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case-control study.

Levine A, Lee W, Figueiredo J, Conti D, VanDenBerg D, Davis B Cancer Causes Control. 2011; 22(4):541-52.

PMID: 21274745 PMC: 3059778. DOI: 10.1007/s10552-011-9726-7.


Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update.

Goodman M, Bostick R, Gross M, Thyagarajan B, Dash C, Flanders W Ann Epidemiol. 2010; 20(12):955-7.

PMID: 21074110 PMC: 3008422. DOI: 10.1016/j.annepidem.2010.08.011.